Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm study of enfortumab vedotin in urothelial cancer after immune checkpoint inhibitor therapy
2017-003479-78Phase 2Completed
- Sponsor
- Seagen
- Start
- May 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin in transitional cell carcinoma (TCC), sponsored by Seagen. Primary endpoint: Confirmed Objective Response Rate. Started May 2018; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2017-003479-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003479-78.